Skip to main
CC
CC logo

Chemours (CC) Stock Forecast & Price Target

Chemours (CC) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 38%
Hold 38%
Sell 0%
Strong Sell 0%

Bulls say

Chemours Co demonstrates significant potential for revenue growth primarily due to its ability to implement price increases in line with market demands for its Flex portal and distribution customers. The company's Titanium Technologies segment, which generates the most revenue, is expected to see improvements in TiO2 margins by 2025, despite near-term challenges from higher raw material costs and weak demand in Europe and Asia. Additionally, Chemours's "Pathway to Thrive" plan aims for considerable cost savings of over $250 million from 2024 to 2027, further strengthening the financial outlook.

Bears say

Chemours faces several fundamental challenges that contribute to a negative outlook on its stock. The company is experiencing a slowdown in demand for HFCs and HFOs due to changing regulations, compounded by competition in HFO technology, which threatens its market position. Additionally, weaknesses in pricing within the TiO2 segment, driven by reduced demand in key end markets such as housing, construction, and automotive, along with broader global economic headwinds, further exacerbate the company's financial pressures.

Chemours (CC) has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 38% recommend Buy, 38% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Chemours and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Chemours (CC) Forecast

Analysts have given Chemours (CC) a Buy based on their latest research and market trends.

According to 8 analysts, Chemours (CC) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Chemours (CC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.